Cargando…

埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析

BACKGROUND AND OBJECTIVE: Targeted therapy has become an indispensable therapy method in advanced non-small cell lung cancer (NSCLC) treatment. Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can significantly prolong the survival of patients harboring EGFR gene mutation. Ic...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999815/
https://www.ncbi.nlm.nih.gov/pubmed/27118647
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.04.04
_version_ 1783331518379196416
collection PubMed
description BACKGROUND AND OBJECTIVE: Targeted therapy has become an indispensable therapy method in advanced non-small cell lung cancer (NSCLC) treatment. Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can significantly prolong the survival of patients harboring EGFR gene mutation. Icotinb is China's first EGFR-TKI with independent intellectual property rights. The aim of this study is to investigate the clinical characteristics about the beneficiary of advanced NSCLC patients with EGFR Common mutation who were treated with Icotinib. Retrospectively collect the data about beneficiary [progression-free survival (PFS)≥6 months] and analysis of the related risk factors for prognosis. METHODS: From September 1, 2011 to September 30, 2015, 231 cases of advanced NSCLC beneficiary with EGFR common mutation were enrolled for treatment with icotinib in Zhejiang Cancer Hospital. RESULTS: The one year benefit rate was 67.9% in the group treated with Icotinib as first line, and in the groupas second line or above was 53.6%, which is statisticallysignificant. The two years benefit rate was 18.7% and 9.3%, respectively. The median PFS of first line group and the second line or above was 16.7 and 12.4 months, respectively. The presence of brain metastasis (P=0.010), Prior chemotherapy (P=0.001), Eastern Cooperative Oncology Group (ECOG) score (P=0.001) were the main factors influencing the prognosis. The most common adverse were skin rashes (51 cases, 22.1%) and diarrhea (27 cases, 11.7%). CONCLUSION: Icotinib offers long-term clinical benefit and good tolerance for advanced NSCLC harboring EGFR gene mutation. Its advantage groups in addition to the patients with brain metastases and better ECOG score, the curative effect of patients with the first-line treatment is superior to second or further line.
format Online
Article
Text
id pubmed-5999815
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59998152018-07-06 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析 Zhongguo Fei Ai Za Zhi 临床研究 BACKGROUND AND OBJECTIVE: Targeted therapy has become an indispensable therapy method in advanced non-small cell lung cancer (NSCLC) treatment. Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) can significantly prolong the survival of patients harboring EGFR gene mutation. Icotinb is China's first EGFR-TKI with independent intellectual property rights. The aim of this study is to investigate the clinical characteristics about the beneficiary of advanced NSCLC patients with EGFR Common mutation who were treated with Icotinib. Retrospectively collect the data about beneficiary [progression-free survival (PFS)≥6 months] and analysis of the related risk factors for prognosis. METHODS: From September 1, 2011 to September 30, 2015, 231 cases of advanced NSCLC beneficiary with EGFR common mutation were enrolled for treatment with icotinib in Zhejiang Cancer Hospital. RESULTS: The one year benefit rate was 67.9% in the group treated with Icotinib as first line, and in the groupas second line or above was 53.6%, which is statisticallysignificant. The two years benefit rate was 18.7% and 9.3%, respectively. The median PFS of first line group and the second line or above was 16.7 and 12.4 months, respectively. The presence of brain metastasis (P=0.010), Prior chemotherapy (P=0.001), Eastern Cooperative Oncology Group (ECOG) score (P=0.001) were the main factors influencing the prognosis. The most common adverse were skin rashes (51 cases, 22.1%) and diarrhea (27 cases, 11.7%). CONCLUSION: Icotinib offers long-term clinical benefit and good tolerance for advanced NSCLC harboring EGFR gene mutation. Its advantage groups in addition to the patients with brain metastases and better ECOG score, the curative effect of patients with the first-line treatment is superior to second or further line. 中国肺癌杂志编辑部 2016-04-20 /pmc/articles/PMC5999815/ /pubmed/27118647 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.04.04 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 临床研究
埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析
title 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析
title_full 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析
title_fullStr 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析
title_full_unstemmed 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析
title_short 埃克替尼治疗EGFR敏感突变的晚期非小细胞肺癌获益患者的临床分析
title_sort 埃克替尼治疗egfr敏感突变的晚期非小细胞肺癌获益患者的临床分析
topic 临床研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999815/
https://www.ncbi.nlm.nih.gov/pubmed/27118647
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.04.04
work_keys_str_mv AT āikètìnízhìliáoegfrmǐngǎntūbiàndewǎnqīfēixiǎoxìbāofèiáihuòyìhuànzhědelínchuángfēnxī
AT āikètìnízhìliáoegfrmǐngǎntūbiàndewǎnqīfēixiǎoxìbāofèiáihuòyìhuànzhědelínchuángfēnxī
AT āikètìnízhìliáoegfrmǐngǎntūbiàndewǎnqīfēixiǎoxìbāofèiáihuòyìhuànzhědelínchuángfēnxī